Aktuell veröffentlichte Forschungsprojekte
The rationale for this study comes from preclinical models, in which lenvatinib decreased the tumor-associated macrophage (TAM) population, which is known as an immune-regulator in the tumor microenvironment. The decrease in TAM population was accompanied by an increase in activated cytotoxic T-cell populations through stimulation of ...
TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the majority of patients with TRK fusion cancer. Because of the limited number of patients treated ...
BAY-1895344 und Pembrolizumab bei ausgewählten Tumoren mit genetischen Alterationen von ATM.